Hyperuricemia as an independent risk factor for major cardiovascular events

Authors:
  • FMFederica Marchese
    Federica Marchese
  • RCRocco Capuano
    Rocco Capuano
  • STSergio Torre
    Sergio Torre
  • AIAnna G. Iannone
    Anna G. Iannone
  • ECEduardo Capuano
    Eduardo Capuano
  • NLNorman Lamaida
    Norman Lamaida
  • MSMatteo Sonderegger
    Matteo Sonderegger
  • ECErnesto Capuano
    Ernesto Capuano

Abstract
To date, whether hyperuricemia may represent a marker or an independent risk factor for cardiovascular disease remains unclear. This study aimed at assessing the role of hyperuricemia in the onset of major cardiovascular events (MACE). Baseline clinical data were collected through a 1998/1999 longitudinal survey as part of the larger Valle dell’Irno Prevenzione Project. Ten years later, MACE incidence was evaluated. A total of 1175 patients (50% men, aged 25–74 years) completed the study. At least one MACE was reported by 135 patients, whose mean uric acid values were significantly higher compared with patients without events (6.0 ± 4.8 and 4.6 ± 4.0 mg/dl, respectively; P < 0.01). Patients with uric acid values of at least 6 mg/dl (prevalence of 14.6%) had significantly lower levels of high-density lipoprotein cholesterol and increased values of BMI, blood pressure (BP), cholesterol, triglycerides, white blood cells, complement component 3 (C3) and creatinine. After subgrouping patients in tertiles and considering the first one as reference [odds ratio (OR): 1], the OR (95% confidence interval) was 1.44 (0.7–2.9) in the second and 2.2 (1.3–3.5) in the third tertile, respectively. Confounder-adjusted stepwise linear regression revealed uric acid, age, creatinine, glucose and systolic BP as independent predictors of MACE. Diastolic BP and creatinine were independently correlated with uric acid in the entire population, diastolic BP only in men and BMI, creatinine, age and C3 in women. Hyperuricemia was shown to be a strong independent risk factor for MACE and should be included in cardiovascular prevention strategies. Whether hypouricemic drugs can decrease cardiovascular disease risk warrants further studies.

This publication has 51 references indexed in Scilit: